• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Bone mineral density testing beneficial for older men receiving androgen deprivation therapy for localized or regional prostate cancer

byMinjee Kim
April 13, 2022
in StudyGraphics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Bone mineral density testing was associated with a significant decreased risk of developing major osteoporotic fractures among older men with localized or regional prostate cancer on androgen deprivation therapy.

2. Bone mineral density screening rates remained low in this patient population and was associated with racial, socioeconomic, and geographic disparities.

Evidence Rating Level: 2 (Good)

Study Rundown: Androgen deprivation therapy (ADT) is the mainstay treatment for locally advanced or metastatic prostate cancer; however, it can negatively impact bone health, resulting in decreased bone mineral density (BMD) on dual x-ray absorptiometry (DXA) and fractures. Although, DXA screening is recommended in this patient population, their association with fracture prevention is unknown. This US nationwide population-based cohort study used data from the Surveillance, Epidemiology, and End Results (SEER) database and the Texas Cancer Registry (TCR) to assess DXA screening and fracture rates among men ≥66 years with localized or regional prostate cancer who were initiating treatment with ADT. The main outcomes included frequencies of DXA screening and fracture, and overall survival, where association was evaluated using a multivariable Cox proportional hazards model with propensity score adjustment. Among 54 953 older men with localized or regional prostate cancer who initiated ADT, DXA screening was associated with a reduction in major fractures. Despite this, the use of DXA screening remained low and was associated with racial, socioeconomic, and geographic disparities. These findings provide further evidence for DXA screening in men with prostate cancer to reduce morbidity and mortality associated with fractures. A limitation of this study was the absence of patients with metastatic disease as most patients had localized or regional disease, limiting the generalizability of the results.

Click to read the study in JAMA Network Open

RELATED REPORTS

2 Minute Medicine: Pharma Roundup – Gastric Immunotherapy Gains, Prostate Pill Expansion, Five-Minute Myeloma Dosing, and Streamlined CAR-T Access [July 8th 2025]

The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave

Exercise improves sexual function in men with prostate cancer  

Click to read an accompanying editorial in JAMA Network Open

In-Depth [retrospective cohort]: This cohort study included 54 953 men (median [range] age, 74 [66-99] years; 4689 [8.5%] Hispanic, 6075 [11.1%] non-Hispanic Black, 41 453 [75.4%] non-Hispanic White, 2736 [5.0%] other ethnicities) diagnosed with prostate cancer between 2005-2015 who initiated treatment with ADT. Data on DXA screening from 12 months prior to 6 months after initial ADT claim was collected from the SEER and TCR Medicare-linked databases. Overall, 4362 men (7.9%) received DXA screening, where the screening rate increased from 6.8% in 2005 to 8.4% in 2015. Screening rates were lower in individuals who were single (OR, 0.89; 95%CI, 0.81-0.97; P = .01), non-Hispanic Black (OR, 0.80; 95%CI, 0.70-0.91; P < .001), from small urban areas (OR, 0.77; 95%CI, 0.66-0.90; P = .001) and areas with lower education levels (OR, 0.75; 95%CI, 0.67-0.83; P < .001), and receiving nonsteroidal androgens (OR, 0.57; 95%CI, 0.39-0.84; P = .004). After initial ADT, 9365 patients (17.5%) developed fractures, where the median time to first fracture was 31 months (IQR, 15-56 months). Among men without previous fractures before ADT, DXA screening was not associated with fracture risk at any site (HR, 0.96; 95%CI, 0.89-1.04; P = .32) but was associated with a decreased risk of major fractures (HR, 0.91; 95%CI, 0.83-1.00; P = .05).

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: bone mineral densitydexadxa screeningfracturesprostateprostate cancerSEER
Previous Post

DNA-based vaccine, ZyCoV-D, is safe and efficacious against COVID-19 infection for patients aged 12 years and older

Next Post

#VisualAbstract: Nivolumab plus chemotherapy improves progression-free survival in gastric or gastroesophageal junction cancer

RelatedReports

2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Pharma

2 Minute Medicine: Pharma Roundup – Gastric Immunotherapy Gains, Prostate Pill Expansion, Five-Minute Myeloma Dosing, and Streamlined CAR-T Access [July 8th 2025]

July 8, 2025
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave

July 2, 2025
Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial
Chronic Disease

Exercise improves sexual function in men with prostate cancer  

May 24, 2025
#VisualAbstract: Infrequent Zoledronate over 10 years Prevents Frcatures in Early Postmenopausal Women
StudyGraphics

#VisualAbstract: Infrequent Zoledronate over 10 years Prevents Frcatures in Early Postmenopausal Women

January 22, 2025
Next Post
#VisualAbstract: Solid organ transplant recipients are at an increased risk of developing non-melanoma skin cancers

#VisualAbstract: Nivolumab plus chemotherapy improves progression-free survival in gastric or gastroesophageal junction cancer

Quick Take: The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomized trial

Initiation of targeted disease-modifying antirheumatic drugs in patients with rheumatoid arthritis not associated with reduced risk of Alzheimer disease and related dementia

Novel coronavirus identified from patients with pneumonia in Wuhan, China

Fewer hospital admissions and death were seen with SARS-CoV-2 Delta (B.1.617.2) compared to Omicron (B.1.1.529) variant infections

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Brain Activation Measured on Functional MRI Predicts Response to Certolizumab, a TNF Inhibitor, in Rheumatoid Arthritis
  • 2 Minute Medicine Rewind July 14, 2025
  • New obesity framework may reclassify over half of overweight individuals as people with obesity
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.